News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Harold J. Burstein: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
Harold J. Burstein/X
Jun 3, 2025, 09:15

Harold J. Burstein: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer

Harold J. Burstein, Breast Cancer Specialist and Professor at Harvard Medical School, posted on X:

“The NEJM has published SERENA-6 data ahead of ASCO25 plenary.
Cami joins other SERDS (elacestrant, imlunestrant, vepdegestrant) with activity in ESR1mut BC
Key questions to think about ahead of session:
1. Intensive ctDNA screening of 10 patients to find 1 who might qualify for ‘switching’ based on ESR1mut. Worthwhile?
2. Does switching among asymptomatic patients with no radiological progression make sense when drug could be added later at progression?
3. Is this fundamentally different than switching treatment based on small upticks in serum tumor markers, without overt progression?
4. Adds to data from EMBER-3 that SERD + CDK46i looks to be effective. Is 2nd line CDK46i now the standard?”

Title: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer

Authors: François-Clément Bidard, Erica L. Mayer, Yeon Hee Park, Wolfgang Janni, Cynthia Ma, Massimo Cristofanilli, Giampaolo Bianchini, Kevin Kalinsky, Hiroji Iwata, Stephen Chia, Peter A. Fasching, Adam Brufsky, Zbigniew Nowecki, Javier Pascual, Lionel Moreau, Shin-Cheh Chen, Nuri Karadurmus, Einav Nili Gal-Yam, Kyung Hae Jung, Sonia Pernas, Sasha McClain, Wei He, Teresa Klinowska, Cynthia Huang-Bartlett, Nicholas C. Turner

Read The Full Article at NEJM.

Harold J. Burstein: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer

More posts featuring ASCO25.

Adam Brufsky cancer Cynthia Huang-Bartlett Cynthia Ma Einav Nili Gal-Yam Erica L. Mayer François-Clément Bidard Giampaolo Bianchini Harold J. Burstein Hiroji Iwata Javier Pascual Kevin Kalinsky Kyung Hae Jung Lionel Moreau Massimo Cristofanilli Nicholas C. Turner Nuri Karadurmus OncoDaily Oncology Peter A. Fasching Sasha McClain Shin-Cheh Chen Sonia Pernas. Stephen Chia Teresa Klinowska Wei He Wolfgang Janni Yeon Hee Park Zbigniew Nowecki
Special Coverage
Blog
Jun 26, 2025, 14:05
Mieke Van Hemelrijck Joined EORTC Board and General Assembly Meetings 2025 in Brussels
Blog
Jun 26, 2025, 13:52
Tracey O’Brien Shared Rare Cancer Patient Hamish’s Story on 2025 Rare Cancers Awareness Day
Blog
Jun 26, 2025, 13:31
Yan Leyfman: Ejaculation Frequency Linked to Lower Prostate Cancer Risk
Insight
Jun 26, 2025, 13:15
Celebrating Innovation, Impact and Empathy in Cancer Care - 2025 CancerX Accelerator Showcase Honored 3 Standout Startups
Blog
Jun 26, 2025, 12:40
Sami Mansfield: How I Help Bridge the Gap in Patient-centered Care - 3 Actionable Strategies for Oncology Teams
Oncolibrary
Jun 26, 2025, 12:32
MASCC 2025: Sarcopenia and CT Fat Metrics Show No Survival Impact in NSCLC
Blog
Jun 26, 2025, 12:13
Andrei Nikiforchin: Honored to Contribute to the New Guideline on Gastric Cancer with Peritoneal Metastases
Blog
Jun 26, 2025, 12:03
Paolo Tarantino: Get Free Registration for 24th IBC East Breast Oncology Conference using the code TARANTINO
Blog
Jun 26, 2025, 11:53
Sendurai Mani: A Week of Insight and Innovation at the Aspen Cancer Conference 2025
Opinion
Jun 26, 2025, 11:16
Elena Castro Discussed Positive Findings from the CAPTURE and AMPLITUDE trials in the ESMO Daily Reporter - ESMO
Blog
Jun 26, 2025, 11:14
Sumanta Pal: Had a Blast Chatting with Walter Stadler and Alan H Bryce at ASCO25 for the City of Hope Podcast
Blog
Jun 26, 2025, 10:44
How Can EU Cancer Policy Best Support Cyprus? - European Cancer Organisation